Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals (SYRS) is a leader in gene regulation research, developing novel therapies for oncology and hematologic malignancies through its integrated platform of assay technologies and bioinformatics. This page provides centralized access to all official company announcements, press releases, and third-party analyses related to SYRS's scientific advancements and corporate developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on SYRS's drug discovery pipeline, financial results, and peer-reviewed research collaborations – all organized for efficient tracking of the company's progress in transforming gene control insights into therapeutic solutions.
Key content categories include clinical trial announcements, FDA regulatory updates, partnership disclosures with academic institutions, quarterly earnings reports, and scientific conference presentations. Each entry is verified for accuracy and relevance to SYRS's core mission of advancing precision medicine through gene regulatory circuit mapping.
Bookmark this page for streamlined monitoring of SYRS's developments in hematologic and oncology research. Check back regularly for authoritative updates on how Syros Pharmaceuticals continues to pioneer new approaches in targeted drug discovery.
Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the randomized portion of its SELECT-AML-1 trial, with initial results expected in Q4 2023. The company received FDA Fast Track designation for tamibarotene in treating higher-risk myelodysplastic syndrome (HR-MDS). Enrollment for the SELECT-MDS-1 trial is on track for completion in Q4 2023, with pivotal data anticipated in Q3 2024. Financially, Syros reported a net loss of $4.8 million for Q4 2022, compared to a loss of $23.8 million in Q4 2021. The company maintains a robust cash position of $202.3 million, expected to fund operations through mid-2025.
Syros Pharmaceuticals (NASDAQ:SYRS) announces CEO Nancy Simonian, M.D., will participate in two investor conferences in March. The first is the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 a.m. ET in Boston, focusing on Novel Oncology Targets. The second event is the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET, conducted virtually. Syros is advancing treatments for hematologic malignancies through its clinical programs, including tamibarotene and SY-2101. For more details, visit www.syros.com.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
